LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah….
Click here to view original post
News
Nusano Named “Researcher of the Year” at Inaugural Best of BioHive Awards
WEST VALLEY CITY, Utah, Feb. 21, 2025 (GLOBE NEWSWIRE) — Nusano, a physics company committed to bringing supply stability and innovation to radioisotope markets, was named “Researcher of the Year” at the inaugural Best of […]
News
dōTERRA Teams Up with Top NBA Trainers to Prep Athletes for New Season
Brand’s renowned essential oils are THE choice of top NBA trainers at Philadelphia 76ers and Orlando Magic PLEASANT GROVE, Utah, July 11, 2023 /PRNewswire/ — The 2023 NBA draft brought in 58 new players to […]
News
ALWAYS BEST CARE SENIOR SERVICES WELCOMES NEW OWNER TO PROVO, ST. GEORGE FRANCHISES
Local Nurse Entrepreneur Steps Up to Meet the Growing Senior Care Needs Throughout Utah PROVO, Utah, March 21, 2025 /PRNewswire/ — Always Best Care Senior Services, one of the leading senior care franchise systems in […]
